Therapeutic Rationale for Endotoxin Removal with Polymyxin B Immobilized Fiber Column (PMX) for Septic Shock

Area of Science:

• Critical care medicine
• Immunology
• Biomaterials

Background:

• Polymyxin B immobilized fiber (PMX) column therapy has been used for sepsis and septic shock since 1994.
• Despite extensive clinical application, a large, multicenter, randomized controlled trial has not yet demonstrated a definitive survival benefit.
• The precise mechanisms by which PMX intervenes in the sepsis cascade and mitigates organ dysfunction remain incompletely understood.

Purpose of the Study:

• To evaluate the ongoing and potential long-term survival benefits of PMX therapy in septic patients.
• To further elucidate the immunomodulatory effects and mechanisms of action of PMX therapy.
• To explore the potential for expanding clinical indications of endotoxin removal therapy through rapid diagnostics.

Main Methods:

• Analysis of findings from a large sepsis clinical trial conducted in North America.
• Ongoing large, multicenter, randomized controlled trial to assess long-term survival benefit.
• In vitro assessment of endotoxin adsorption capacity and in vivo studies in animal models.
• Detailed analysis of large clinical databases to support survival benefit claims.

Main Results:

• PMX therapy has demonstrated effectiveness and usefulness for over 25 years in clinical practice.
• Surface antigen expression on monocytes and neutrophils shows improvement post-PMX therapy.
• Immunomodulatory effects, potentially beyond endotoxin removal, are suggested as contributing to improved organ function.

Conclusions:

• Further research, including ongoing trials and data analysis, is crucial to definitively establish the survival benefit of PMX therapy.
• Understanding the detailed mechanisms of PMX is key to optimizing its application in sepsis and potentially other endotoxemia-related diseases.
• Developing rapid diagnostics for endotoxemia could enable precision medicine and broaden the use of endotoxin removal therapies.